Funder: National Institutes of Health (NIH)
Due Dates: June 23, 2025 | October 21, 2024 | March 4, 2024
Funding Amounts: Up to $1,050,000 total direct costs over 3 years
Summary: Supports early-phase, investigator-initiated clinical trials of natural products to replicate target engagement and assess associations with clinical outcomes.
Key Information: Clinical trial (R33) mechanism; hypothesis-driven, milestone-based; excludes efficacy/effectiveness or cancer treatment trials; requires FDA regulatory compliance if applicable.